Obesity and pulmonary hypertension

Abstract Pulmonary hypertension, defined as a mean pulmonary artery pressure (PAP) > 25 mmHg, is a serious condition that can lead to right heart failure and death. It can result from a wide variety of disease processes, many of which are highly prevalent in obese populations. The exact rates of pulmonary hypertension in patients with obesity remain unclear but appear high. Emerging data from animal models suggest some pathologic mechanisms by which obesity and the metabolic syndrome may contribute to the development of pulmonary vascular disease, but the roles of the majority of these mechanisms in the development of pulmonary hypertension in human subjects are yet to be elucidated.

• Publication year

  2019

• Venue

  Mechanisms and Manifestations of Obesity in Lung Disease

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1016/B978-0-12-813553-2.00009-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4.

  2017cited by this paper
• Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry

  2017cited by this paper
• The effect of BMI on haemostasis: Implications for thrombosis in women's health.

  2017cited by this paper
• The prevalence of pulmonary hypertension in patients with obesity hypoventilation syndrome: a prospective observational study.

  2017cited by this paper
• Oxidized LDL Is Associated With Metabolic Syndrome Traits Independently of Central Obesity and Insulin Resistance

  2016cited by this paper
• Weight Change and Risk of Venous Thromboembolism: The Tromsø Study

  2016cited by this paper
• Role of Oxidized Lipids in Pulmonary Arterial Hypertension

  2016cited by this paper
• Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.

  2016cited by this paper
• The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension.

  2016cited by this paper
• Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments.

  2016cited by this paper
• Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea

  2016cited by this paper
• Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors.

  2016cited by this paper
• Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomy

  2016cited by this paper
• Leptin signalling system as a target for pulmonary arterial hypertension therapy

  2015cited by this paper
• Leptin knockout attenuates hypoxia-induced pulmonary arterial hypertension by inhibiting proliferation of pulmonary arterial smooth muscle cells.

  2015cited by this paper
• Redox Biology in Pulmonary Arterial Hypertension (2013 Grover Conference Series)

  2015cited by this paper
• Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.

  2015cited by this paper
• Proinflammatory High-Density Lipoprotein Results from Oxidized Lipid Mediators in the Pathogenesis of Both Idiopathic and Associated Types of Pulmonary Arterial Hypertension

  2015cited by this paper
• OSA and pulmonary hypertension: time for a new look.

  2015cited by this paper
• Poor Agreement between Pulmonary Capillary Wedge Pressure and Left Ventricular End-Diastolic Pressure in a Veteran Population

  2014cited by this paper
• Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension

  2014cited by this paper
• Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.

  2014cited by this paper
• Obesity-Related Pulmonary Arterial Hypertension in Rats Correlates with Increased Circulating Inflammatory Cytokines and Lipids and with Oxidant Damage in the Arterial Wall but not with Hypoxia

  2014cited by this paper
• Impact of insulin resistance on ventricular function in pulmonary arterial hypertension.

  2014cited by this paper
• Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.

  2014cited by this paper
• The Metabolic Theory of Pulmonary Arterial Hypertension

  2014cited by this paper
• Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension

  2014cited by this paper
• Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p

  2014cited by this paper
• Right Ventricular Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study

  2014cited by this paper
• Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

  2014cited by this paper
• Fat, fire and muscle--the role of adiponectin in pulmonary vascular inflammation and remodeling.

  2013cited by this paper
• Dysregulation of Ubiquitin-Proteasome Pathway and Apolipoprotein a Metabolism in Sickle Cell Disease–Related Pulmonary Arterial Hypertension

  2013cited by this paper
• Uncoupling Protein 2 Deficiency Mimics the Effects of Hypoxia and Endoplasmic Reticulum Stress on Mitochondria and Triggers Pseudohypoxic Pulmonary Vascular Remodeling and Pulmonary Hypertension

  2013cited by this paper
• Genetics and genomics of pulmonary arterial hypertension.

  2013cited by this paper
• Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.

  2013cited by this paper
• Pulmonary hypertension due to left heart diseases.

  2013cited by this paper
• The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox".

  2013cited by this paper
• Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension.

  2012cited by this paper
• Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension

  2012cited by this paper
• Contemporary Reviews in Cardiovascular Medicine Pulmonary Hypertension Due to Left Heart Disease

  2012cited by this paper
• Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort

  2012cited by this paper
• Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

  2012cited by this paper
• Pulmonary hypertension due to left heart disease in the adult — a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation

  2012cited by this paper
• A potential role for insulin resistance in experimental pulmonary hypertension

  2012cited by this paper
• Leptin levels predict survival in pulmonary arterial hypertension

  2012cited by this paper
• Concise Review: Adipocyte Origins: Weighing the Possibilities

  2011cited by this paper
• Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT

  2011cited by this paper
• Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?

  2011cited by this paper
• Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions.

  2011cited by this paper
• Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey

  2011cited by this paper
• Pulmonary hypertension in obesity-hypoventilation syndrome.

  2011cited by this paper
• Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

  2011cited by this paper
• Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction

  2011cited by this paper
• Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction.

  2010cited by this paper
• Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension.

  2010cited by this paper
• Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man

  2010cited by this paper
• Lung Endothelial Dysfunction in Congestive Heart Failure: Role of Impaired Ca2+ Signaling and Cytoskeletal Reorganization

  2010cited by this paper
• Chronic thromboembolic pulmonary hypertension.

  2010cited by this paper
• The protective role of adiponectin in pulmonary vascular disease.

  2010cited by this paper
• The obesity paradox: perception vs knowledge.

  2010cited by this paper
• Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

  2010cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.

  2009cited by this paper
• Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease.

  2009cited by this paper
• Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology

  2009cited by this paper
• Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease.

  2009cited by this paper
• Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population

  2009cited by this paper
• Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling.

  2009cited by this paper
• Association of the metabolic syndrome with pulmonary venous hypertension.

  2009cited by this paper
• Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome.

  2009cited by this paper
• Role of obesity in cardiomyopathy and pulmonary hypertension.

  2009cited by this paper
• An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

  2008cited by this paper
• Insulin resistance in pulmonary arterial hypertension

  2008cited by this paper
• Alveolar gas diffusion abnormalities in heart failure.

  2008cited by this paper
• Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects.

  2008cited by this paper
• Risk factors for chronic thromboembolic pulmonary hypertension

  2008cited by this paper
• Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation

  2007cited by this paper
• Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle.

  2007cited by this paper
• An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry.

  2007cited by this paper
• Pathology of pulmonary hypertension.

  2007cited by this paper
• Severe pulmonary hypertension in postmenopausal obese women.

  2006cited by this paper
• Uncoupling proteins, dietary fat and the metabolic syndrome

  2006cited by this paper
• Association of subclinical right ventricular dysfunction with obesity.

  2006cited by this paper
• Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism.

  2006cited by this paper
• The obesity paradox: body mass index and outcomes in patients with heart failure.

  2005cited by this paper
• Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure

  2005cited by this paper
• Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner*

  2005cited by this paper
• Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.

  2004cited by this paper
• Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.

  2004cited by this paper
• Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell

  2002cited by this paper
• Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects

  2001cited by this paper
• The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases.

  2001cited by this paper
• The relationship between obesity and mortality in patients with heart failure.

  2001cited by this paper
• Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.

  2000cited by this paper
• Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.

  1996cited by this paper
• Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

  1996cited by this paper
• Pulmonary Hemodynamics in the Obstructive Sleep Apnea Syndrome: Results in 220 Consecutive Patients

  1996cited by this paper
• Vulnerability of pulmonary capillaries in heart disease.

  1995cited by this paper
• Sleep apnea and sleep disruption in obese patients.

  1994cited by this paper
• Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure

  1992cited by this paper

• No citing papers are available for this paper.